24,440 results match your criteria glioblastoma cells


Integrated analysis of programmed cell death ligand 1 expression reveals increased levels in high-grade glioma.

J Cancer Res Clin Oncol 2021 May 8. Epub 2021 May 8.

Institute of Pathology, University Hospital Salzburg, Paracelsus Medical University, Müllner Hauptstr. 48, 5020, Salzburg, Austria.

Purpose: Gliomas are the most frequent primary brain tumors of adults. Despite intensive research, there are still no targeted therapies available. Here, we performed an integrated analysis of glioma and programmed cell death ligand 1 (PD-L1) in 90 samples including 58 glioma and 32 control brain tissues. Read More

View Article and Full-Text PDF

Novel facets of glioma invasion.

Int Rev Cell Mol Biol 2021 17;360:33-64. Epub 2020 Oct 17.

NORLUX Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg, Luxembourg; Department of Biomedicine, University of Bergen, Bergen, Norway. Electronic address:

Malignant gliomas including Glioblastoma (GBM) are characterized by extensive diffuse tumor cell infiltration throughout the brain, which represents a major challenge in clinical disease management. While surgical resection is beneficial for patient outcome, it is well recognized that tumor cells at the invasive front or beyond stay behind and constitute a major source of tumor recurrence. Invasive glioma cells also represent a difficult therapeutic target since they are localized within normal functional brain areas with an intact blood brain barrier (BBB), thereby excluding most systemic drug treatments. Read More

View Article and Full-Text PDF
October 2020

The study of Raddeanin A cerebrovascular endothelial cell trafficking through P-glycoprotein.

Biochem Biophys Res Commun 2021 May 4;559:222-229. Epub 2021 May 4.

Key Laboratory of Traditional Chinese Medicine Analysis, School of Pharmaceutical Sciences, Changchun University of Traditional Chinese Medicine, Changchun, 130117, China. Electronic address:

As one of the natural triterpenoids isolated from Anemone Raddeana Regel, Raddeanin A (RA) has been confirmed to possess therapeutic effects against multiple tumorigeneses, especially for the onset of glioblastoma and growth in human brains. However, the mechanism by which this happens remains poorly understood in terms of the vascular endothelium trafficking routine of RA through the brain-blood barrier (BBB). To seek such answers, human brain microenvironment endothelial cells (HBMECs) were used to stimulate the microenvironment in vitro, and to explore the intracellular accumulation of RA. Read More

View Article and Full-Text PDF

Novel CTRP8-RXFP1-JAK3-STAT3 axis promotes Cdc42-dependent actin remodeling for enhanced filopodia formation and motility in human glioblastoma cells.

Mol Oncol 2021 May 7. Epub 2021 May 7.

Depts. of Human Anatomy and Cell Science, University of Manitoba, Winnipeg, Canada.

CTRP8 is the least studied member of the C1Q-TNF related peptide family. We identified CTRP8 as a ligand of the G protein coupled receptor RXFP1 in glioblastoma multiforme (GBM). The CTRP8-RXFP1 ligand-receptor system protects human GBM cells against the DNA alkylating damage inducing temozolomide (TMZ), the drug of choice for the treatment of patients with GBM. Read More

View Article and Full-Text PDF

From neural stem cells to glioblastoma: A natural history of GBM recapitulated in vitro.

J Cell Physiol 2021 May 7. Epub 2021 May 7.

Molecular Oncology Laboratory MOL, Departamento de Fisioloxía, Centro Singular de Investigación en Medicina Molecular e Enfermidades Crónicas CiMUS, Facultade de Medicina, Universidade de Santiago de Compostela, Instituto de Investigación Sanitaria de Santiago de Compostela IDIS, Santiago de Compostela, Spain.

Due to its aggressive and invasive nature glioblastoma (GBM), the most common and aggressive primary brain tumour in adults, remains almost invariably lethal. Significant advances in the last several years have elucidated much of the molecular and genetic complexities of GBM. However, GBM exhibits a vast genetic variation and a wide diversity of phenotypes that have complicated the development of effective therapeutic strategies. Read More

View Article and Full-Text PDF

BRCA1 Protein Expression Predicts Survival in Glioblastoma Patients from an NRG Oncology RTOG Cohort.

Oncology 2021 May 6:1-9. Epub 2021 May 6.

Department of Radiation Oncology, Weill Cornell Medicine, New York, New York, USA.

Purpose: Glioblastoma, the most common malignant brain tumor, was associated with a median survival of <1 year in the pre-temozolomide (TMZ) era. Despite advances in molecular and genetic profiling studies identifying several predictive biomarkers, none has been translated into routine clinical use. Our aim was to investigate the prognostic significance of a panel of diverse cellular molecular markers of tumor formation and growth in an annotated glioblastoma tissue microarray (TMA). Read More

View Article and Full-Text PDF

Enhancement of Cancer Cell-Killing Effects of Boron Neutron Capture Therapy by Manipulating the Expression of L-Type Amino Acid Transporter 1.

Radiat Res 2021 May 6. Epub 2021 May 6.

Research Reactor Institute, Kyoto University, Kyoto, Japan.

In this study, we examined whether the cancer cell-killing effects of boron neutron capture therapy (BNCT) are enhanced by manipulating the expression levels of l-type amino acid transporter 1 (LAT1) of human cancer cells, which transports boronophenylalanine into cells. We transfected pCMV/LAT1-GFP plasmids into a T98G glioblastoma cell line and selected several clones. Confocal laser microscopic observation was performed to confirm the stable overexpression of LAT1 in the plasma membranes of the clones. Read More

View Article and Full-Text PDF

Screening and Identification of LMNB1 and DLGAP5, Two Key Biomarkers in Gliomas.

Biosci Rep 2021 May 6. Epub 2021 May 6.

Insititute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, China.

Glioma is the most common primary cancer in the central nervous system.  Despite advances in surgery, radiotherapy, and chemotherapy over the past decades, the prognosis of glioblastoma patients remains poor.  We aim to identify robust gene signatures to better understand the complex molecular mechanisms and to discover potential novel molecular biomarkers for glioma. Read More

View Article and Full-Text PDF

Parenteral high‑dose ascorbate - A possible approach for the treatment of glioblastoma (Review).

Int J Oncol 2021 Jun 6;58(6). Epub 2021 May 6.

Department of Nutritional Biochemistry, University of Hohenheim, D‑70599 Stuttgart, Germany.

For glioblastoma, the treatment with standard of care therapy comprising resection, radiation, and temozolomide results in overall survival of approximately 14-18 months after initial diagnosis. Even though several new therapy approaches are under investigation, it is difficult to achieve life prolongation and/or improvement of patient's quality of life. The aggressiveness and progression of glioblastoma is initially orchestrated by the biological complexity of its genetic phenotype and ability to respond to cancer therapy via changing its molecular patterns, thereby developing resistance. Read More

View Article and Full-Text PDF

WDR81 Gene Silencing Can Reduce Exosome Levels in Human U87-MG Glioblastoma Cells.

J Mol Neurosci 2021 May 6. Epub 2021 May 6.

Stem Cell Research Center, Golestan University of Medical Sciences, Gorgan, Iran.

Glioblastoma is a very invasive and prevalent brain tumor that affects 15 in 100,000 persons over the age of 70 years. Studies have shown that the expression of the WD repeat domain 81 (WDR81) gene, which is effective in vesicular transport and inhibition of autophagy, is increased in glioblastoma. The decreased autophagy was found to be related to the increased production of exosomes, which is a major factor in the pathogenesis of glioblastoma. Read More

View Article and Full-Text PDF

A metastasis suppressor Pt-dendrimer nanozyme for the alleviation of glioblastoma.

J Mater Chem B 2021 May 6. Epub 2021 May 6.

Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea. and KHU-KIST Department of Converging Science and Technology, Kyung Hee University, Seoul 02447, Republic of Korea and Department of Anatomy and Neurobiology, College of Medicine, Kyung Hee University, Seoul 02447, Republic of Korea and Center for Converging Humanities, Kyung Hee University, Seoul 02447, Republic of Korea and Medical Research Center for Bioreaction to Reactive Oxygen Species and Biomedical Science Institute, School of Medicine, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.

Nanozymes are nanostructure-based materials which mimic the enzymatic characteristics of natural enzymes. Biological applications of nanozymes have been highlighted in basic research, industry, and translational medicine as a new cutting-edge tool. In this work, and for the first time, we disclose a tumor alleviation property of a nanozyme that is made up of amine-terminated sixth-generation polyamidoamine dendrimers with encapsulated tiny platinum nanoparticles. Read More

View Article and Full-Text PDF

Knock-Down of Mucolipin 1 Channel Promotes Tumor Progression and Invasion in Human Glioblastoma Cell Lines.

Front Oncol 2021 19;11:578928. Epub 2021 Apr 19.

Immunopathology Laboratory, School of Pharmacy, University of Camerino, Camerino, Italy.

Among cancers that affect the central nervous system, glioblastoma is the most common. Given the negative prognostic significance of transient receptor potential mucolipin 1 (TRPML1) channel reduction in patients with glioblastoma, as discussed in previous publications, the aim of the current study was to investigate the biological advantage of TRPML1 loss for glioma cells. Human glioblastoma primary cancer cells (FSL and FCL) and glioblastoma cell lines (T98 and U251) were used for that purpose. Read More

View Article and Full-Text PDF

Establishment of a Novel Temozolomide Resistant Subline of Glioblastoma Multiforme Cells and Comparative Transcriptome Analysis With Parental Cells.

Anticancer Res 2021 May;41(5):2333-2347

Division of Plastic and Reconstructive Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.;

Background/aim: Glioblastoma multiforme (GBM) is a lethal disease with a high rate of chemoresistance to temozolomide (TMZ). The aim of the study was to establish a TMZ-resistant subline from the GBM-8401 cell line to determine the mechanisms of resistance and identify novel effective therapeutics for TMZ-resistant GBM.

Materials And Methods: Comparative transcriptome analysis of GBM-8401/TMZR cells and the parental line was performed using Ion Torrent sequencing. Read More

View Article and Full-Text PDF

Thymidine decreases the DNA damage and apoptosis caused by tumor-treating fields in cancer cell lines.

Genes Genomics 2021 May 5. Epub 2021 May 5.

School of Biosystems and Biomedical Sciences, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul, 02841, Republic of Korea.

Background: Tumor-treating fields (TTFields) is an emerging non-invasive cancer-treatment modality using alternating electric fields with low intensities and an intermediate range of frequency. TTFields affects an extensive range of charged and polarizable cellular factors known to be involved in cell division. However, it causes side-effects, such as DNA damage and apoptosis, in healthy cells. Read More

View Article and Full-Text PDF

Propolis Extract Regulate microRNA Expression in Glioblastoma and Brain Cancer Stem Cells.

Anticancer Agents Med Chem 2021 May 3. Epub 2021 May 3.

Ege University, Faculty of Medicine, Department of Pediatrics, Izmir, Turkey.

Background: Grade IV gliomas are classified as glioblastoma (GBM), which is the most malignant brain cancer type. Various genetic and epigenetic mechanisms play a role in the initiation and progression of GBM. MicroRNAs (miRNAs) are small, non-coding RNA molecules that are the main epigenetic regulatory RNA class. Read More

View Article and Full-Text PDF

MR1 overexpression correlates with poor clinical prognosis in glioma patients.

Neurooncol Adv 2021 Jan-Dec;3(1):vdab034. Epub 2021 Feb 20.

Department of Neurological Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.

Background: Glioblastoma is the most common adult primary brain tumor with near-universal fatality. Major histocompatibility complex (MHC) class I molecules are important mediators of CD8 activation and can be downregulated by cancer cells to escape immune surveillance. MR1 is a nonclassical MHC-I-like molecule responsible for the activation of a subset of T cells. Read More

View Article and Full-Text PDF
February 2021

LHPP impedes energy metabolism by inducing ubiquitin-mediated degradation of PKM2 in glioblastoma.

Am J Cancer Res 2021 15;11(4):1369-1390. Epub 2021 Apr 15.

The Second School of Clinical Medicine, Southern Medical University Guangzhou 510000, P. R. China.

Phospholysine phosphohistidine inorganic pyrophosphate phosphatase (LHPP) is a new-found tumor suppressor in a variety of tumors. While, it is still unknown about its role in glioma. In this study, we found that LHPP is abnormally decreasing or absent in glioblastoma, and the low expression of LHPP is associated with poor median survival in glioma patients. Read More

View Article and Full-Text PDF

AKIP1 promotes glioblastoma viability, mobility and chemoradiation resistance via regulating CXCL1 and CXCL8 mediated NF-κB and AKT pathways.

Am J Cancer Res 2021 15;11(4):1185-1205. Epub 2021 Apr 15.

Department of Neurosurgery, The First Clinical College of Harbin Medical University Nangang District, Harbin 150001, China.

This study aimed to investigate the interaction of A-kinase-interacting protein 1 (AKIP1) with C-X-C motif chemokine ligand (CXCL)1, CXCL2, CXCL8, and their effects on regulating glioblastoma multiforme (GBM) malignant behaviors. AKIP1 expression was modified by pcDNA and pGPH1 vectors in U-87 MG and U-251 MG cells. Subsequently, multiple compensative experiments were conducted via adding CXCL1, CXCL2 and CXCL8 in the pGPH1-AKIP1 (AKIP1 knockdown) transfected U-87 MG and U-251 MG cells, respectively. Read More

View Article and Full-Text PDF

Cilostazol eliminates radiation-resistant glioblastoma by re-evoking big conductance calcium-activated potassium channel activity.

Am J Cancer Res 2021 15;11(4):1148-1169. Epub 2021 Apr 15.

Institute of Basic Medical Sciences, National Cheng Kung University Hospital Taiwan.

In spite of radio- and chemotherapy, glioblastoma (GBM) develops therapeutic resistance leading to recurrence and poor prognosis. Therefore, understanding the underlying mechanisms of resistance is important to improve the treatment of GBM. To this end, we developed a radiation-resistant cell model by exposure to consecutive periods of irradiation. Read More

View Article and Full-Text PDF

Tumor-treating fields (TTFields)-based cocktail therapy: a novel blueprint for glioblastoma treatment.

Am J Cancer Res 2021 15;11(4):1069-1086. Epub 2021 Apr 15.

Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan 430022, China.

Glioblastoma is one of the most common malignant tumors in the central nervous system. Due to the high plasticity, heterogeneity and complexity of the tumor microenvironment, these tumors are resistant to almost all therapeutic strategies when they reach an advanced stage. Along with being a unique and effective way to kill cancer cells, tumor-treating fields (TTFields) has emerged as a breakthrough among glioblastoma therapies since the advent of temozolomide (TMZ), and the combination of these treatments has gradually been promoted and applied in the clinic. Read More

View Article and Full-Text PDF

Docetaxel-loaded folate-modified TPGS-transfersomes for glioblastoma multiforme treatment.

Mater Sci Eng C Mater Biol Appl 2021 May 20;124:112033. Epub 2021 Mar 20.

School of Pharmaceutical Science of Ribeirao Preto, University of Sao Paulo (USP), Ribeirao Preto, São Paulo, Brazil. Electronic address:

Glioblastoma multiforme (GBM) is a first primary Central Nervous System tumor with high incidence and lethality. Its treatment is hampered by the difficulty to overcome the blood-brain barrier (BBB) and by the non-specificity of chemotherapeutics to tumor cells. This study was based on the development characterization and in vitro efficacy of folate-modified TPGS transfersomes containing docetaxel (TF-DTX-FA) to improve GBM treatment. Read More

View Article and Full-Text PDF

Exploiting the anticancer effects of a nitrogen bisphosphonate nanomedicine for glioblastoma multiforme.

J Nanobiotechnology 2021 May 4;19(1):127. Epub 2021 May 4.

School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, UK.

Glioblastoma multiforme (GBM) is an incurable aggressive brain cancer in which current treatment strategies have demonstrated limited survival benefit. In recent years, nitrogen-containing bisphosphonates (N-BPs) have demonstrated direct anticancer effects in a number of tumour types including GBM. In this study, a nano-formulation with the RALA peptide was used to complex the N-BP, alendronate (ALN) into nanoparticles (NPs) < 200 nm for optimal endocytic uptake. Read More

View Article and Full-Text PDF

Bioscaffold-based study of glioblastoma cell behavior and drug delivery for tumor therapy.

Neurochem Int 2021 May 1:105049. Epub 2021 May 1.

Department of Biological Sciences, Wichita State University, 1845 Fairmount, Wichita, KS, 67260, USA. Electronic address:

Glioblastoma multiforme (GBM) is a severe form of brain cancer with an average five-year survival rate of 6.7%. Current treatment strategies include surgical resection of the tumor area and lining the lesion site with therapeutics, which offer only a moderate impact on increasing survival rates. Read More

View Article and Full-Text PDF

Novel dopamine receptor 3 antagonists inhibit the growth of primary and temozolomide resistant glioblastoma cells.

PLoS One 2021 4;16(5):e0250649. Epub 2021 May 4.

Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, United States of America.

Treatment for the lethal primary adult brain tumor glioblastoma (GBM) includes the chemotherapy temozolomide (TMZ), but TMZ resistance is common and correlates with promoter methylation of the DNA repair enzyme O-6-methylguanine-DNA methyltransferase (MGMT). To improve treatment of GBMs, including those resistant to TMZ, we explored the potential of targeting dopamine receptor signaling. We found that dopamine receptor 3 (DRD3) is expressed in GBM and is also a previously unexplored target for therapy. Read More

View Article and Full-Text PDF

Telmisartan attenuates human glioblastoma cells proliferation and oncogenicity by inducing the lipid oxidation.

Asia Pac J Clin Oncol 2021 May 4. Epub 2021 May 4.

Center of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China.

Background: Glioblastoma (GBM) is one of the most common primary brain tumors, which accounts up to 80% of malignant brain tumors and the 5-year relative survival rate is below 5%. Recent studies showed that the lipid metabolism played an essential role in GBM development. As a peroxisome proliferators-activated receptors γ (PPAR-γ) agonist, telmisartan improves the lipid metabolism and has been used to treat hypertension for long time. Read More

View Article and Full-Text PDF

LncRNA GAS8-AS1 downregulates lncRNA NEAT1 to inhibit glioblastoma cell proliferation.

Brain Behav 2021 May 4:e02128. Epub 2021 May 4.

Department of Neurology, People's Hospital of Deyang City, Deyang, China.

Background: LncRNA GAS8-AS1 has been reported to participate in several types of cancer, while its role in glioblastoma (GBM) is unknown. In the present study, we aimed to investigate the function of GAS8-AS1 in GBM and the underlying mechanisms.

Methods: The expression levels of GAS8-AS1 and NEAT1 in GBM patients and the healthy controls were measured by performing RT-qPCR. Read More

View Article and Full-Text PDF

MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Review.

Neuro Oncol 2021 Apr 30. Epub 2021 Apr 30.

Bristol Medical School: Brain Tumour Research Centre, Population Health Sciences, University of Bristol, Bristol, UK.

Background: The DNA repair protein O6 methylguanine-DNA methyltransferase (MGMT) causes resistance of tumour cells to alkylating agents. It is a predictive biomarker in high grade gliomas treated with temozolomide, however there is no consensus on which test method, methylation sites, and cut-off values to use.

Methods: We performed a Cochrane Review to examine studies using different techniques to measure MGMT and predict survival in glioblastoma patients treated with temozolomide. Read More

View Article and Full-Text PDF

COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells.

BMC Cancer 2021 May 3;21(1):493. Epub 2021 May 3.

Department of Pharmaceutical Biochemistry, Poznan University of Medical Sciences, Poznań, Poland.

Background: Glioblastoma (GBM) is the deadliest and the most common primary brain tumor in adults. The invasiveness and proliferation of GBM cells can be decreased through the inhibition of Wnt/β-catenin pathway. In this regard, celecoxib is a promising agent, but other COXIBs and 2,5-dimethylcelecoxib (2,5-DMC) await elucidation. Read More

View Article and Full-Text PDF

Epigenetic Modification of MicroRNA-219-1 and Its Association with Glioblastoma Multiforme.

Biochemistry (Mosc) 2021 Apr;86(4):420-432

Department of Clinical Biochemistry, School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, 1449614535, Iran.

MicroRNA-219-1 (miR-219-1) acts as a tumor suppressor in a variety of cancers but, the regulatory epigenetic mechanism involved in its gene expression level has not been studied. Using real-time polymerase chain reaction (real-time PCR) and bisulfite genomic sequencing technology, promoter methylation level of miR-219-1 and gene expression levels of miR-219-5p and miR-219-1-3p were determined respectively, in glioblastoma multiforme (GBM) (n = 31), their adjacent normal tissues (n = 31), and GBM U87 cell line. Following treatment of GBM U87 cells with 5-aza-2'-deoxycitidine (5-aza-dC), miR-219-1 promoter methylation, their target mRNA, and protein levels were determined by genomic bisulfite modification, real-time-PCR, and ELISA techniques, respectively. Read More

View Article and Full-Text PDF

LncRNA MIR31HG is activated by STAT1 and facilitates glioblastoma cell growth via Wnt/β-catenin signaling pathway.

Neurosci Res 2021 Apr 30. Epub 2021 Apr 30.

Neurosurgery Department, Marina Bay Central Hospital, Dongguan, 523899, Guangdong, China. Electronic address:

Long non-coding RNAs (lncRNAs) have been reported to biologically regulate tumor progression. LncRNA MIR31HG has been identified as an oncogene in several cancer types, but its role and mechanism in glioblastoma (GBM) remain to be explored. In the present study, we detected strongly-expressed MIR31HG in GBM cells through RT-qPCR analysis. Read More

View Article and Full-Text PDF